Buchumschlag

From multiplex serology to serolomics: a novel approach to the antibody response against the SARS-CoV-2 proteome

The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We, therefore, aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Butt, Julia (VerfasserIn) , Murugan, Rajagopal (VerfasserIn) , Wenz, Theresa (VerfasserIn) , Olberg, Sylvia (VerfasserIn) , van Straaten, Monique (VerfasserIn) , Wardemann, Hedda (VerfasserIn) , Stebbins, Erec (VerfasserIn) , Kräusslich, Hans-Georg (VerfasserIn) , Bartenschlager, Ralf (VerfasserIn) , Brenner, Hermann (VerfasserIn) , Laketa, Vibor (VerfasserIn) , Schöttker, Ben (VerfasserIn) , Müller, Barbara (VerfasserIn) , Merle, Uta (VerfasserIn) , Waterboer, Tim (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 24 April 2021
In: Viruses
Year: 2021, Jahrgang: 13, Heft: 5, Pages: 1-17
ISSN:1999-4915
DOI:10.3390/v13050749
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/v13050749
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4915/13/5/749
Volltext
Verfasserangaben:Julia Butt, Rajagopal Murugan, Theresa Hippchen, Sylvia Olberg, Monique van Straaten, Hedda Wardemann, Erec Stebbins, Hans-Georg Kräusslich, Ralf Bartenschlager, Hermann Brenner, Vibor Laketa, Ben Schöttker, Barbara Müller, Uta Merle and Tim Waterboer
Beschreibung
Zusammenfassung:The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We, therefore, aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV-2 proteome. Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance was assessed in a COVID-19 case cohort (n = 48 hospitalized patients from Heidelberg) as well as n = 85 age- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial enzyme-linked immunosorbent (ELISA) assays. A sensitivity of 100% (95% CI: 86-100%) was achieved in COVID-19 patients 14 days post symptom onset with dual sero-positivity to SARS-CoV-2 N and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96-100%). Antibody responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody response. This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero-prevalence.
Beschreibung:Gesehen am 25.06.2021
Beschreibung:Online Resource
ISSN:1999-4915
DOI:10.3390/v13050749

Ähnliche Einträge